These findings reveal that an ACADL-dependent mechanoresponsive pathway responds to increasing matrix stiffness (the biomechanical signals in the tumor microenvironment) and promotes HCC progression through lipid metabolic reprogramming, thereby providing a new therapeutic target for HCC treatment. Here, ACADL is linked to neoplasm.